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ABSTRACT
Neonatal diabetes mellitus (NDM), defined as
persistent hyperglycemia occurring in the first
months of life, is a rare cause of hyperglycemia
and is often misdiagnosed as type 1 diabetes
mellitus (T1DM). Numerous reports have
shown that the successful transition from
insulin to sulfonylurea agents can be achieved
in up to 90% of patients with NDM. However,
most of the reports pertain to infants; the
literature is limited regarding treatment of
adults with NDM. We present our experience
with a patient with permanent NDM, initially
misdiagnosed as T1DM, who subsequently was
successfully transitioned to oral sulfonylurea
therapy after 37 years of insulin dependence.




Neonatal diabetes mellitus (NDM), defined as
persistent hyperglycemia occurring in the first
six months of life, is a rare cause of
hyperglycemia with an estimated incidence of
1 in 100,000 to 1 in 260,000 live births [1–3].
Almost all cases of NDM have monogenic
etiology in contrast to the autoimmune
diabetes presenting in children beyond
6 months of age [4]. There are 22 known
genetic causes of NDM (mutations in 21 genes
and methylation abnormalities at the 6q24
locus) that identify different clinical subtypes
of the disease [1]. This includes transient NDM
(TNDM), permanent NDM (PNDM), and
complex syndromes in which NDM is often
the presenting feature (i.e., Wolcott–Rallison
syndrome) [1]. The most common cause of
NDM are mutations in the adenosine
triphosphate (ATP)-sensitive potassium
channel (K-ATP channel) subunit genes
ABCC8 and KCNJ11 which regulate the release
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of insulin from pancreatic b cells [1, 5–8]. The
pancreatic b-cell K-ATP channels are
hetero-octamers assembled by four Kir6.2
subunits and four high-affinity sulfonylurea
receptor 1 (SUR1) subunits encoded by the
genes KCNJ11and ABCC8, respectively [9–11].
KCNJ11 mutations are more frequent in
patients with PNDM, whereas mutations in
ABCC8 cause TNDM more frequently [8]. The
majority of infants with NDM are small for
gestational age, which may be related to
decreased insulin secretion in the fetus and
exhibit postnatal catch-up growth with insulin
therapy [12]. The most severe defect includes
marked developmental delay and early onset
epilepsy, also known as DEND syndrome [8, 10].
Subcutaneous insulin was routinely used in
the past to treat patients with this disorder;
however, studies have shown that the successful
transition from insulin to sulfonylurea (SU)
agents can be achieved in up to 90% of
patients with NDM [11]. We report a case of
PNDM whose treatment was successfully
transitioned from insulin to oral SU therapy
after 37 years of insulin dependence.
CLINICAL CASE
A 37-year-old man with history of poorly
controlled diabetes with multiple
microvascular complications of proliferative
diabetic retinopathy, stage 3 chronic kidney
disease (CKD) and peripheral neuropathy,
presented to our institution for further
evaluation. The patient reported frequent
hypoglycemia and blood glucose (BG)
excursions with BG ranging from 48–330 mg/
dL. Review of his medical records demonstrated
previous hemoglobin A1c (HbA1c) measures as
high as 12.9%. He was diagnosed with ‘‘type 1
diabetes mellitus’’ (T1DM) when he was 2 weeks
old and multiple daily injections of insulin
(MDI) were initiated to control glycemia. He
reported a strong family history of early-onset
insulin-dependent diabetes in both of his
siblings, and his mother had
insulin-dependent diabetes mellitus (unknown
type). The patient’s medical and family history
warranted further investigation and
consideration of other forms of diabetes.
HbA1c was 7.7%, C-peptide\0.2 ng/mL (range
0.8–3.2 ng/mL) with corresponding BG of
80 mg/dL (65–100 mg/dL; Table 1). Testing for
pancreatic islet cell and glutamic acid
decarboxylase antibodies was negative. The
patient’s physical exam, and specifically the
patient’s neurological status, was otherwise
normal. As genetic testing could not be
afforded by the patient, a trial of SU therapy
was offered. Glimepiride 2 mg daily (QD) was
initiated and slowly titrated up to 8 mg twice
daily (BID) over a 3-month period with an
observed increase in C-peptide from
undetectable to 0.7 ng/dL (BG 176 mg/dL).
Glimepiride was then increased to 12 mg BID
with further improvement in glycemic control.
Insulin detemir and insulin lispro were slowly
decreased as the dose of SU therapy was
increased. In an attempt to increase the
patient’s own endogenous insulin production
and achieve further insulin independence, a
7-day trial of sitagliptin 100 mg QD was
initiated with a subsequent increase in
C-peptide to 0.9 ng/dL (BG 252 mg/dL).
However, glycemic control did not improve so
the sitagliptin was discontinued and a trial of
dapagliflozin 5 mg QD was initiated (despite his
CKD stage 3). Glycemic control significantly
improved, and after dapagliflozin was increased
to 10 mg QD, insulin therapy was completely
discontinued (his original total daily dose of
insulin was 64 units). The patient follows a
carbohydrate-controlled diet of approximately
45 g per meal and occasionally takes 3 units of
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insulin lispro when planning to eat a high
carbohydrate containing meal, particularly
when eating out at restaurants. The addition
of the sodium-glucose cotransporter-2 (SGLT2)
inhibitor has helped tremendously with
postprandial glucose control and the patient
has not had any episodes of diabetic
ketoacidosis. Repeat HbA1c after 3 months of
oral anti-diabetic therapy was 6.6%, with
average BG in the 70–130 mg/dL range. Over
the last year since the initiation of SU therapy,
his HbA1c has remained below 7% without any
episodes of hypoglycemia (Table 2). Multiple
attempts to evaluate and test his parents and
siblings for NDM have been unsuccessful thus
far.
Informed consent was obtained from the
patient for publication of this case report.





HbA1c, % Insulin regimen 1 dose of SU
7/28/14 \0.2 80 7.3 Det 27 units ? Lis 7-15-15 and GLIM 2 mg QD was
added after labs obtained
7/30/14 0.3 291
7/31/14 Increased GLIM 4 mg QD
8/4/14 0.4 263 Det 22 units ? Lis 7-15-15 ? GLIM 4 mg QD
8/12/14 0.5 306 Changed Det to 18 units ? Lis 7-14-12 ? increased
GLIM to 4 mg BID
8/29/14 0.7 321
9/17/14 Increased GLIM to 8 mg BID, decreased Lis to 3-6-5
9/24/14 0.7 178 Det 18 units ? Lis 3-6-5 ? GLIM 8 mg BID
9/25/14 Decreased Lis to 3 units with meals
10/6/14 Stopped mealtime Lis, increased GLIM 12 mg BID
10/20/14 0.7 175 7.0 Det 15 units ? GLIM 12 mg BID, Lis PRN, add
sitagliptin 100 mg QD
10/28/14 0.9 252 Det 15 units ? GLIM 12 mg BID, stop sitagliptin,
start dapagliﬂozin 5 mg QD
2/23/15 0.6 219 6.6 Det 10 units ? GLIM 12 mg BID ? dapagliﬂozin
10 mg QD ? Lis PRN, 45 g of CHO per meal
2/25/15 Decreased Det to 6 units
3/4/15 GLIM 12 mg BID and dapagliﬂozin 10 mg QD,
stopped Det
7/15/15 168 6.9% GLIM 12 mg BID and dapagliﬂozin 10 mg
QD ? Lis 3 units PRN for ‘‘high CHO’’ meal
11/16/15 148 6.8
BID twice daily, CHO carbohydrate, Det insulin detemir, GLIM glimepiride, HbA1c hemoglobin A1c, Lis insulin lispro,
PRN pro re nata (as needed), QD daily, SU sulfonylurea
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DISCUSSION
NDM is a monogenic form of diabetes that
presents within the first six months of life. In
approximately half of patients, the diabetes will
be permanent, and in the remaining cases the
diabetes will remit within a fewweeks ormonths
although it might relapse later in life [10].
Approximately, two-thirds of TNDM cases are
caused by abnormalities in an imprinted region
on chromosome 6q24 [13, 14] with activating
mutations in either of the genes encoding the
two subunits of the K-ATP channel of the b-cell
membrane (KCNJ11 or ABCC8) causing the
majority of the remaining cases [15].
In contrast, the genetic abnormality
responsible for up to 30% of PNDM cases
remains unknown although the commonest
known cause in outbred populations is
mutations in theK-ATP channel or INS genes [10].
Heterozygous activating mutations in the
KCNJ11 or ABCC8 gene, which encodes the
Kir6.2 subunits and SUR1 regulatory subunits of
the K-ATP channel, respectively, have been
implicated and account for 30% to 58% of
cases of PNDM diagnosed in patients less than
6 months of age [6, 11]. Mutations in the K-ATP
channels lead to decreased sensitivity to ATP
inhibition; consequently, the channels remain
open in the presence of glucose, thereby
reducing insulin secretion [11]. SUs close
K-ATP channels by an ATP-independent route
thereby causing insulin secretion. Studies have
shown that many patients with diabetes caused
by KCNJ11 or ABCC8 mutations can
successfully switch from treatment with
insulin to oral SU therapy [11]. The dose of SU
therapy that is required to manage glycemia in
patients with NDM, particularly to achieve
insulin independence, is often higher than the
maximum recommended dose for the
treatment of type 2 diabetes mellitus [11],
typically needing around 0.5 mg/kg/day of
glibenclamide [11, 16]. In our case, glimepiride
was chosen instead of glibenclamide (glyburide)
because of the ever-evolving literature reporting
a lower risk of hypoglycemia [17] and lower risk
of all-cause and cardiovascular-related mortality
with the other readily available SUs compared
to glibenclamide [18, 19].
A report by Thurber et al. [20] found that, in
patients with NDM, earlier age at initiation of
SU treatment was associated with an improved
response to SU therapy. This led the authors to
appropriately hypothesize that perhaps the
declining sensitivity to SU therapy observed
with more advanced age may be due to the loss
of b-cell mass over time in those treated with
insulin therapy, thereby highlighting the
importance of early recognition and initiation
of SU therapy.
In our patient, we were able to demonstrate
a rise in C-peptide as the SU dosage was
increased. While it is certainly possible that
the original C-peptide may have been
undetectable because the patient did not
follow directions (drink orange juice prior to
laboratory assessment to ensure BG is over
200 mg/dL) the observed gradual rise in
C-peptide, in the setting of hyperglycemia, as
the SU dose was increased, demonstrates a slow
increase in endogenous insulin secretion in
response to the therapy. The patient did follow
the directions to raise serum glucose[200 mg/
dL at the time of subsequent C-peptide
measures, as demonstrated in Table 1.
While the lack of genetic testing is a
significant limitation of our report, this
Table 2 HbA1c% trend
Year 2008 2009 2010 2011 2014 2015
HbA1c% 12.9 11.7 11.2 9.4 7.7 6.6
HbA1c hemoglobin A1c
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limitation does not take away from the main
point of this report, that being the importance
of performing a very thorough personal and
family history in patients who present with a
prior diagnosis of diabetes, particularly T1DM
very early in life, as a near-miraculous
transformation in management may be
possible in a minority of patients, as was the
case in our patient, even if genetic testing is not
available/feasible. Other means to obtain
genetic testing on this patient are actively
being pursued. Genetic testing for some
conditions is available free of charge on a
research basis in certain academic institutions
in patients diagnosed with diabetes before
6 months of age (e.g., [21–23]) [10].
To the best of our knowledge, we are the first
to report the effective and safe use of SGLT2
inhibitors in a patient with NDM. While the
HbA1c did not appear to improve significantly
after the addition of dapagliflozin, the therapy
did help to lower postprandial glycemic
excursions, not adequately addressed by the
SU therapy, and helped to reduce the frequency
at which the patient took a correction dose of
bolus insulin, or a dose of bolus insulin to assist
with glycemic control when he consumed
higher carbohydrate containing meals.
CONCLUSIONS
Wereport the case of a patientwith long-standing
poorly controlled NDM initially misdiagnosed
and treated as having T1DM. Many patients with
NDM treatedwith insulin-only therapy behave as
brittle diabetics, with difficult to control glycemia
leading to complications. The addition or
transition to SU therapy may help some of these
patients achieve better glycemic control, while
requiring lessdependenceon insulin therapy.Our
case highlights the importance of history taking
in the management of patients with diabetes,
especially the need to conduct a thorough family
history, as recognition of NDM can profoundly
impact the diabetes-related management of both
the patient and their family members.
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